Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: Synergistic effect of combination with interferon-α

Antiviral Research

Volumn 64, Issue 3, 2004, Pages 195-201

  Yanagida, Koichiro ^a,b   Baba, Chiaki ^a,c   Baba, Masanori ^a  

^a Grad Sch Med Dent Sci K   (Japan)

^b ASAHI KASEI PHARMA CORPORATION   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

BVDV; Combination; HCV; Interferon; Mizoribine

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MIZORIBINE; NUCLEOSIDE ANALOG; RIBAVIRIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BOVINE DIARRHEA VIRUS; CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG INHIBITION; FLAVIVIRUS; HERPES SIMPLEX VIRUS; KIDNEY CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANIMALS; CATTLE; DIARRHEA VIRUSES, BOVINE VIRAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEPACIVIRUS; INTERFERON-ALPHA; RIBAVIRIN; RIBONUCLEOSIDES; TUMOR CELLS, CULTURED;

ANIMALIA; BOVINAE; BOVINE VIRAL DIARRHEA VIRUS 1; FLAVIVIRIDAE; HEPATITIS C VIRUS;

EID: 8644225553     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2004.09.001     Document Type: Article

References (29)

1. M.S. Belen'kii, and R.F. Schinazi Multiple drug effect analysis with confidence interval Antiviral Res. 25 1994 1 11
2. H.C. Bodenheimer, K.L. Lindsay, G.L. Davis, J.H. Lewis, S.N. Thung, and L.B. Seeff Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial Hepatology 26 1997 473 477
3. D.L. Brassard, M.J. Grace, and R.W. Bordens Interferon-α as an immunotherapeutic protein J. Leukoc. Biol. 71 2002 565 581
4. V.E. Buckwold, B.E. Beer, and R.O. Donis Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents Antiviral Res. 60 2003 1 15
5. V.E. Buckwold, J. Wei, M. Wenzel-Mathers, and J. Russell Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication Antimicrob. Agents Chemother. 47 2003 2293 2298
6. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
7. A.M. Contreras, Y. Hiasa, W. He, A. Terella, E.V. Schmidt, and R.T. Chung Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system J. Virol. 76 2002 8505 8517
8. S. Crotty, C.E. Cameron, and R. Andino RNA virus error catastrophe: direct molecular test by using ribavirin Proc. Natl. Acad. Sci. U.S.A. 98 2001 6895 6900
9. G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, C. Trepo, M.L. Shiffman, S. Zeuzem, A. Craxi, M.H. Ling, and J. Albrecht Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C N. Engl. J. Med. 339 1998 1493 1499
10. S. Goodbourn, L. Didcock, and R.E. Randall Interferons: cell signaling, immune modulation, antiviral response and virus countermeasures J. Gen. Virol. 81 2000 2341 2364
11. M. Hosoya, S. Shigeta, T. Ishii, H. Suzuki, and E. De Clercq Comparative inhibitory effects of various nucleoside and nonnucleoside analogue on replication of influenza virus types A and B in vitro and in vivo J. Infect. Dis. 168 1993 641 646
12. K. Inoue, K. Sekiyama, M. Yamada, T. Watanabe, H. Yasuda, and M. Yoshiba Combined interferon-α2b and cyclosporine A in the treatment of chronic hepatitis C: controlled trial J. Gastroenterol. 38 2003 567 572
13. H. Ishikawa Mizoribine and mycophenolate mofetil Curr. Med. Chem. 6 1999 575 597
14. J. Larkin, L. Jin, M. Farmen, D. Venable, Y. Huang, S.L. Tan, and J.I. Glass Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system J. Interferon Cytokine Res. 23 2003 247 257
15. P. Leyssen, E. De Clercq, and J. Neyts Perspectives for the treatment of infections with Flaviviridae Clin. Microbiol. Rev. 13 2000 67 82
16. T.J. Liang, B. Rehermann, L.B. Seeff, and J.H. Hoofnagle Pathogenesis, natural history, treatment and prevention of hepatitis C Ann. Intern. Med. 132 2000 296 305
17. D. Maag, C. Castro, Z. Hong, and C.E. Cameron Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin J. Biol. Chem. 276 2001 46094 46098
18. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, Z.D. Goodman, M.H. Ling, S. Cort, and J.K. Albrecht Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N. Engl. J. Med. 339 1998 1485 1492
19. K. Mizuno, M. Tsujino, M. Takeda, M. Hayashi, K. Atsumi, K. Asano, and T. Matsuda Studies on bredinin I. Isolation, characterization and biological properties J. Antibiot. 27 1974 775 782
20. K. Moriishi, and Y. Matsuura Mechanisms of hepatitis C virus infection Antiviral Chem. Chemother. 14 2003 285 297
21. J.H. Nam, J. Bukh, R.H. Purcell, and S.U. Emerson High-level expression of hepatitis C virus (HCV) structural proteins by a chimeric HCV/BVDV genome propagated as a BVDV pseudotype J. Virol. Methods 97 2001 113 123
22. S. Ouzounov, A. Mehta, R.A. Dwek, T.M. Block, and R. Jordan The combination of interferon α-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy Antiviral Res. 55 2002 425 435
23. S. Pancheva, D. Dundarova, and M. Remichkova Potentiating effect of mizoribine on the anti-herpes virus activity of acyclovir Z. Naturforsch. C 57 2002 902 904
24. O. Reichard, G. Norkrans, A. Fryden, J.H. Braconier, A. Sonnerborg, and O. Weiland Randomized, double-blind, placebo-controlled trial of interferon-α-2b with and without ribavirin for chronic hepatitis C Lancet 351 1998 83 87
25. L.J. Stuyver, S. Lostia, S.E. Patterson, J.L. Clark, K.A. Watanabe, M.J. Otto, and K.W. Pankiewicz Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhoea virus agents Antiviral Chem. Chemother. 13 2002 345 352
26. L.J. Stuyver, T. Whitaker, T.R. McBrayer, B.I. Hernandez-Samtiago, S. Lostia, P.M. Tharnish, M. Ramesh, C.K. Chu, R. Jordan, J. Shi, S. Rachakonda, K.A. Watanabe, M.J. Otto, and R.F. Schinazi Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture Antimicrob. Agents Chemother. 47 2003 244 254
27. Y. Tanabe, N. Sakamoto, N. Enomoto, M. Kurosaki, E. Ueda, S. Maekawa, T. Yamashiro, M. Nakagawa, C.H. Chen, N. Kanazawa, S. Kakinuma, and M. Watanabe Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-α J. Infect. Dis. 189 2004 1129 1139
28. K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282 1288
29. S. Zhou, R. Liu, B.M. Baroudy, B.A. Malcolm, and G.R. Reyes The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA Virology 310 2003 333 342